Background: The role of the cerebellum in coordinating mental activity is supported by its connections with cerebral regions involved in cognitive/affective functioning, with decreased activities on functional neuroimaging observed in the cerebellum of schizophrenia patients performing mental tasks. Brain-derived neurotrophic factor (BDNF)-induced activation of tyrosine kinase B (TrkB) is essential to synaptic plasticity. We hypothesized that alterations in BDNF and TrkB expression in the cerebellum were associated with schizophrenia and affective disorders. Methods: We employed immunohistochemistry and immunoblotting to quantify protein expression of BDNF and TrkB in the cerebellum of patients with schizophrenia, bipolar disorder, and major depression compared to controls (n = 15 each). Results: While TrkB immunoreactivity in each of the molecular and granule-cell layers was reduced in all 3 disease groups (12-34%) compared to the control (P = 0.018 and 0.038, respectively, ANOVA), only the reduction in bipolar disorder remained statistically significant upon Tukey-Kramer post hoc analyses (P = 0.019 and 0.021, respectively). Apparent decreases in BDNF immunoreactivity in all 3 disease groups (12-30%) compared to the control were not statistically significant. TrkB immunoreactivity was not significantly associated with any of the demographic, clinical, and postmortem variables. Immunoblotting displayed an 85-kDa TrkBimmunoreactive band, consistent with a truncated isoform, in all 60 cases. Limitations: On immunoblotting, apparent decreases in 85-kDa-TrkB levels in all 3 disease groups compared to the control were not statistically significant. Conclusions: Our finding of reduced TrkB expression in bipolar disorder suggests that dysregulation of TrkB-mediated neurotrophin signaling in the cerebellum may play a role in the pathophysiology of this disease.
Introduction
The cerebellum connects with diverse regions of the cerebral cortex via the cortico-ponto-cerebello-thalamo-cortical circuit, suggesting its involvement in coordinating or modulating several different cognitive domains, in addition to its wellestablished role in motor coordination and procedural skill learning (Andreasen and Pierson, 2008; Ito, 2008; Konarski et al., 2005) . Specifically, the prefrontal cortex has been shown in non-human primates to connect primarily with the lateral crus II and vermal lobules VII and IX of the cerebellar cortex and the ventral dentate nucleus (Ramnani, 2006) . In healthy subjects performing a variety of mental tasks, functional neuroimaging data revealed simultaneous alterations in activation of the cerebellum, thalamus, and appropriate task-dependent cerebral Journal of Affective Disorders 133 (2011) 646-654 cortical regions (Andreasen and Pierson, 2008; Ito, 2008; Konarski et al., 2005) . Accordingly, attempts have been made to study the role of the cerebellum in diverse symptoms of major psychiatric disorders (Konarski et al., 2005; Rapoport et al., 2000) . Decreased activities on functional neuroimaging were observed in several cerebellar regions both in the vermis and hemispheres of patients with schizophrenia performing a broad range of mental tasks (Andreasen et al., 1996) . A recent review by Picard et al. (2008) suggested that clinical evidence for cerebellar dysfunction in schizophrenia seemed clearly defined in some domains such as neurological soft signs, posture, or equilibrium, but the evidence was limited with regard to cognition. Focal cerebellar lesions have been linked to bipolar disorder-like symptoms in sporadic case reports (Lauterbach, 1996) . Patients with bipolar disorder demonstrated performance and timing deficits in a single-cue delay eyeblink conditioning task, suggesting cerebellar dysfunction in associative learning (Bolbecker et al., 2009 ).
Brain-derived neurotrophic factor (BDNF) and its highaffinity receptor tyrosine kinase B (TrkB) are widely expressed in the central nervous system (CNS) and play a crucial role in regulating synaptic transmission and plasticity during development and adulthood (Bramham and Messaoudi, 2005; Cohen-Cory et al., 2010; Ohira and Hayashi, 2009; Twiss et al., 2006) . In addition to full-length TrkB (TrkB-FL) with an intact tyrosine kinase domain, alternative splicing of the TrkB premRNA generates C-terminus-truncated isoforms lacking tyrosine kinase, such as T1 and T-Shc isoforms found in the human brain (Luberg et al., 2010) . In the adult primate cerebellum, BDNF and TrkB are expressed in almost all Purkinje and granule cells (Ohira and Hayashi, 2003) .
The Val66Met allele of BDNF was associated with selective minor cognitive deficits in subjects with schizophrenia, bipolar disorder, or unaffected controls, while the Val66Val BDNF allele seemed to confer an increased risk of early-onset and rapidcycling variants of bipolar disorder (Post, 2007) . Postmortem studies revealed changes in mRNA and protein expression of BDNF and TrkB in the prefrontal cortex, anterior cingulate cortex, and hippocampus of patients with schizophrenia (Durany et al., 2001; Hashimoto et al., 2005; Iritani et al., 2003; Takahashi et al., 2000; Weickert et al., 2003) . Using in situ hybridization, Thompson Ray et al. (2011) found reductions in BDNF mRNA levels in the hippocampal CA4 of patients with bipolar disorder. Additionally, there were region-specific decreases in TrkB-FL mRNA levels in the CA4 of schizophrenia patients and the layer-II entorhinal cortex of patients with bipolar disorder and major depression. In the cerebellum of schizophrenia subjects, an autopsy study showed increased BDNF mRNA expression in the crus I (Paz et al., 2006) .
In the present study, we aimed at studying protein expression levels of BDNF and TrkB in the cerebellar inferior semilunar lobule (i.e., crus II) of patients with schizophrenia, bipolar disorder, and major depression in comparison to those levels found in unaffected control subjects. We used immunoperoxidase staining on frozen tissue sections and measured immunoreactivity by quantitative two-dimensional image analysis. The presence of TrkB isoforms in the cerebellar cortical tissue was confirmed by immunoblotting. We hypothesized that alterations in BDNF and TrkB expression in the lateral cerebellum were associated with schizophrenia and affective disorders.
Methods

Study samples
Coded postmortem cerebellar tissue specimens (primarily the inferior semilunar lobule) were obtained from the Stanley Foundation Neuropathology Consortium, consisting of four diagnostic groups (n= 15 each): schizophrenia, bipolar disorder (11 with and 4 without psychosis), major depression without psychotic features, and unaffected controls. DSM-IV diagnoses were made independently by two psychiatrists (Torrey et al., 2000) . Experiments were performed without knowledge of subject diagnoses until attainment of the results.
Immunohistochemistry
The primary antibodies used were rabbit polyclonal anti-BDNF (H-117, #sc-20981, Santa Cruz Biotechnology, Santa Cruz, CA, USA) raised against amino acids 130-247 of human BDNF and targeting mature BDNF, and rabbit polyclonal antiTrkB (H-181, #sc-8316, Santa Cruz Biotechnology) raised against amino acids 160-340 of human TrkB and targeting TrkB-FL, TrkB-T1, and TrkB-T-Shc isoforms (Anger et al., 2007; Tan and Shepherd, 2006) . Both of the antibodies were used at 1:75 dilution in Dako antibody diluent (DakoCytomation, Carpinteria, CA, USA).
Fourteen micrometer-thick frozen tissue sections on 1.5 ×3 in. microscopy slides (1 slide per case for each primary antibody) were thawed from −70°C to room temperature (RT), fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) (4°C, 10 min), washed with PBS, incubated with 0.3% hydrogen peroxide/PBS (RT, 30 min) to quench endogenous peroxidase, washed with PBS, and incubated with 5% normal goat serum/PBS (RT, 30 min). The sections were incubated with the primary antibody in humidified boxes (4°C, 24 h). After rinsing with 0.1% Tween-20/PBS (PBS-T), the sections were incubated with Envision+™ peroxidase-labeled polymer conjugated goat anti-rabbit Ig reagent (DakoCytomation) (RT, 40 min). After rinsing with PBS-T, the sections were incubated with diaminobenzidine (ImmPACT™ DAB Peroxidase Substrate, Vector Laboratories, Burlingame, CA, USA) (RT, 5 min). After water washing, the sections were dehydrated through a graded ethanol series, cleared with xylene, and mounted with Cytoseal 60 (Richard-Allan Scientific, Waltham, MA, USA). For the negative reagent control, the primary antibody was omitted.
Quantification of immunohistochemical reactivity
The immunoreactive signals were quantitatively assessed by means of two-dimensional computer-assisted image analysis as previously described (Soontornniyomkij et al., 2010) . Briefly, the immunostained slides were imaged using a color camera mounted on a microscope fitted with a Prior ProScan II motorized stage. With precise movement of the motorized stage controlled by the Stage-Pro module of the Image-Pro Plus software (version 4.5, Media Cybernetics, Bethesda, MD, USA), 640 × 480 pixel full-color image frames were contiguously captured within a scan area with the ×10 objective lens (the resolution being approximately 2 μm/pixel). The Stage-Pro combined all the frames into a single tiled image of the entire scan area. The same settings on the microscope (e.g., illumination, filters, and aperture), camera, and Image-Pro Plus for image acquisition were uniformly applied to all 60 cases.
On each image, the outline of each area of interest (AOI; i.e., the molecular layer and granule-cell layer) was digitally delineated with the Image-Pro Plus software ( Fig. 1A and B , respectively). The edges of tissue sections were excluded to avoid staining artifacts, as were large vascular spaces and areas of tissue folding. To measure immunoreactive signals within AOI, RGB color segmentation was set to best select the specific signal while ignoring the nonspecific background. The same setting of color segmentation was uniformly applied to all four measurements (i.e., BDNF/molecular layer, BDNF/granule-cell layer, TrkB/ molecular layer, and TrkB/granule-cell layer) in all 60 cases. 
Immunoblot analysis
Frozen cerebellar cortical tissue (200 mg per case) was homogenized on ice in 1 ml of lysis buffer (50 mM Tris, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100; pH 7.6) supplemented with Complete Proteinase Inhibitor Cocktail (#04693116001, Roche Diagnostics, Indianapolis, IN, USA). The homogenates were centrifuged at 10,000 g (4°C, 10 min) and supernatants were collected and assayed for total protein using the Micro BCA Protein Assay kit (#23235, Thermo Scientific, Rockford, IL, USA). Equal amounts of extracted protein from 60 cases were thoroughly mixed to generate the 60-case pool for serving as a gel-to-gel control (Chong et al., 2008 . The separated proteins were electroblotted onto ImmunBlot PVDF membranes (#162-0176, Bio-Rad) (100 V/350 mA, 60 min). The membranes were blocked with 5% nonfat milk in 0.1% Tween-20/Tris-buffered saline (TBS-T) (RT, 3 h) and then incubated (4°C, 16 h) with the rabbit polyclonal anti-TrkB antibody (H-181, #sc-8316, Santa Cruz Biotechnology; 1:500 dilution in 1% nonfat milk/TBS-T) or the mouse monoclonal anti-β-actin antibody (AC-15, #ab6276, Abcam, Cambridge, MA, USA; 1:20,000). After TBS-T washing, the membranes were incubated (RT, 2 h) with the peroxidase-conjugated goat antirabbit IgG secondary antibody (#170-6515, Bio-Rad; 1:5,000 dilution in 1% nonfat milk/TBS-T) or peroxidase-conjugated horse anti-mouse IgG secondary antibody (#PI-2000, Vector Laboratories; 1:5,000). After TBS-T washing, the signals were developed using the enhanced chemiluminescence substrate (Western Lighting® Plus-ECL, #NEL104001EA, PerkinElmer, Waltham, MA, USA) and captured using the Gel Logic 2200 Imaging System (Carestream Health, Rochester, NY, USA). The signal intensity in each band was measured using the ImageJ software (NIH, Bethesda, MD, USA). To control for lane-to-lane variability, each TrkB value of 60 cases was divided by the β-actin value in the same lane, as was each TrkB value of the 60-case pool. To control for gel-to-gel variability, each β-actin-normalized TrkB value of 60 cases was divided by the β-actin-normalized TrkB value of the 60-case pool in the same gel. For each case, immunoblot analysis was run in duplicate and the average value of normalized signal intensity was used.
Statistical analysis
The distribution of continuous variables in a given group was evaluated for normality using the Shapiro-Wilk W test. Among these variables, only values of the lifetime quantity of antipsychotic drugs and the BDNF IRn were in most instances not normally distributed and hence were log 10 -transformed prior to further statistical analysis. Accordingly, appropriate parametric methods were applied including paired and unpaired Student's t-tests, one-way analysis of variance (ANOVA) with the Tukey-Kramer-honestly significant difference post hoc test, and Pearson correlation (r) coefficient. In case there were significant correlations between the BDNF or TrkB IRn and the potential confounding continuous variables (e.g., age at death, postmortem interval, brain pH, and brain weight) in each of the four diagnostic groups, analysis of covariance (ANCOVA) was performed. The equality of group variances was assessed either by the F test for two variances or the Bartlett's test for three or more variances. In case there was a significant difference among group variances, the Welch's correction was applied. The Fisher's exact or Chi-square (χ 2 ) test was used to determine associations among categorical proportions. The JMP® Version 8.0.2 for Macintosh software (SAS, Cary, NC, USA) was used to perform all statistical analyses. Values of continuous variables were expressed as "mean± standard deviation (SD)". All P values calculated were two-tailed and considered statistically significant at a threshold of P b 0.05.
Results
The four diagnostic groups were matched for the age at death, sex, race, postmortem interval, brain pH, and brain weight (Table 1) . Patients with major depression were first diagnosed at older age than those individuals with schizophrenia (P=0.016) and bipolar disorder (P =0.005, Tukey-Kramer post hoc test); nonetheless, no significant disease group difference in the duration of disease was observed. The severity of substance abuse (i.e., none-little-social [n =42], past moderate-heavy [n =6], and current moderate-heavy [n =11]), but not the severity of alcohol abuse (n =34, 11, and 14, respectively), was significantly different across the four diagnostic groups (χ 2 =13.848, df=6, P = 0.031). Antipsychotic drugs were used by 14 of 15 schizophrenia patients (the lifetime quantity: 1,000-200,000 mg of fluphenazine equivalent) and by 12 of 15 patients with bipolar disorder (200-60,000 mg); no significant difference between these two diagnostic groups was observed with regard to the proportion of patients receiving drugs or the log 10 -transformed lifetime quantity of drugs. The proportion of committed suicide was not significantly different among schizophrenia, bipolar disorder, and major depression. A significant diagnostic group difference was observed in the storage time for frozen brain tissues (range = 31-938 days, F = 5.349, df = 3;56, P = 0.003, ANOVA), where the brains of patients with schizophrenia and bipolar disorder were kept frozen longer than the control (P = 0.009 and 0.010, respectively, Tukey-Kramer post hoc test).
BDNF immunoreactivity
Immunoreactive signals for BDNF varied in intensity among the cases studied. The molecular layer showed diffuse weak immunoreactivity. A subpopulation of Purkinje cells exhibited intense immunoreactivity in soma and apical dendrites. The granule-cell layer was diffusely and moderately immunoreactive (Fig. 1C) . The log 10 -transformed BDNF IRn across all 60 cases was significantly higher in the granulecell layer (1.45 ± 0.23) than in the molecular layer (1.33 ± 48.1 ± 10.7 44.5 ± 13.1 42.3 ± 11.7 46.5 ± 9.3 F(3,56) = 0.728, P = 0.54 Sex (n): male, female 9, 6 9, 6 9, 6 9, 6 χ 2 (3) = 0, P = 1 0.27; t = 5.47, df = 59, P b 0.0001, paired t-test) with effective pairing (r = 0.788, P b 0.0001).
In the molecular and granule-cell layers, the BDNF IRn was apparently decreased in schizophrenia (18% and 16%, respectively), bipolar disorder (26% and 21%, respectively), and major depression (30% and 12%, respectively) compared to the control (Table 2) . Nonetheless, there were no significant differences in the log 10 -transformed BDNF IRn across the four diagnostic groups on ANOVA (Table 2) , nor were there with regard to sex, committed suicide, psychosis, severity of substance abuse, or severity of alcohol abuse (Table 3 ). In each of the four diagnostic groups, no significant linear correlations were found between the log 10 -transformed BDNF IRn either in the molecular or granule-cell layer and the age at death, postmortem interval, brain pH, and brain weight, except that in schizophrenia there was moderate inverse correlation between the log 10 -transformed BDNF IRn in the molecular layer and the postmortem interval (r=−0.523, P=0.046); therefore, ANCOVA was not performed.
TrkB immunoreactivity
Immunoreactive signals for TrkB were found to vary in intensity from one case to another. The molecular layer was weakly to moderately immunoreactive. A subpopulation of Purkinje cells showed intense immunoreactivity in soma and apical dendrites. The granule-cell layer was diffusely and intensely immunoreactive (Fig. 1D) . The TrkB IRn was significantly higher in the granule-cell layer (44.67 ± 14.17) than in the molecular layer (28.32 ± 11.22; t = 15.056, df= 59, P b 0.0001, paired t-test), with effective pairing (r =0.805, P b 0.0001).
In each of the molecular (Fig. 2 ) and granule-cell layers, there was a significant difference in the TrkB IRn across the four diagnostic groups (F = 3.626 and 2.998, df = 3;56, P =0.018 and 0.038, respectively, ANOVA), with the apparent reduction of TrkB IRn in schizophrenia (12% and 12%, respectively), bipolar disorder (34% and 29%, respectively), and major depression (26% and 12%, respectively) compared to the control. Post hoc analyses demonstrated that the TrkB IRn reduction was statistically significant only in bipolar disorder relative to the control (P = 0.019 and 0.021, respectively, Tukey-Kramer post hoc test, Table 2 ). In each of the four diagnostic groups, no significant linear correlations were found between the TrkB IRn either in the molecular or granule-cell layer and the age at death, postmortem interval, brain pH, and brain weight, except that in major depression there was moderate direct correlation between the TrkB IRn in the granule-cell layer and the age at death (r = 0.524, P =0.045); accordingly, ANCOVA was not performed.
Either in the molecular or granule-cell layer, there were no significant differences in the TrkB IRn with regard to sex, committed suicide, severity of substance abuse, or severity of alcohol abuse (Table 3) . Concerning psychosis, no significant differences in the TrkB IRn in the molecular and granule-cell layers were found between the psychotic (i.e., schizophrenia and psychotic bipolar disorder) and non-psychotic (i.e., nonpsychotic bipolar disorder, major depression, and controls) groups (Table 3) . Although there was a significant difference in the age at disease onset across 3 disease groups (F = 6.631, df= 2;42, P = 0.003, ANOVA, Table 1 ), no significant linear correlation was found between the TrkB IRn either in the molecular or granule-cell layer and the age at disease onset in schizophrenia, bipolar disorder, or major depression, nor was it observed with the duration of disease ( Table 2 ). The TrkB IRn either in the molecular or granule-cell layer was not significantly correlated with the lifetime quantity of antipsychotic drugs in schizophrenia or bipolar disorder. In each of 4 diagnostic groups, the storage time for frozen brain tissues showed no significant correlation with the TrkB IRn either in the molecular or granule-cell layer (Table 2) , although there was a significant diagnostic group difference in the storage time for frozen brain tissues (Table 1) .
Immunoblot analysis
The immunoblot analysis (Fig. 3) revealed one TrkBimmunoreactive band of approximately 85 kDa, consistent with a C-terminus-truncated TrkB-T1 isoform (Luberg et al., 2010) , in all 60 cases, although a faint TrkB-immunoreactive band of approximately 120 kDa was also observed in occasional cases. A β-actin-immunoreactive band of approximately 42 kDa was consistently present in all lanes. On analysis of the 85-kDa-TrkB signal intensity, the values in two schizophrenia cases were greater than two standard deviations from the mean in this diagnostic group and hence excluded (Chong et al., 2008) . The 85-kDa-TrkB levels appeared decreased in schizophrenia (24%), bipolar disorder (11%), and major depression (16%) compared to the control (mean= 0.78, 0.92, 0.87, and 1.03, SD = 0.27, 0.26, 0.24, and 0.40, respectively); however, no statistical significance was reached (F = 1.637, df = 3;54, P = 0.19, ANOVA).
Discussion
The immunoreactive patterns of BDNF and TrkB observed in the adult human cerebellum in the present study were similar to those reported in the human (Murer et al., 1999; Murer et al., 2001 ) and monkey (Ohira et al., 2004; Ohira and Hayashi, 2003) brains. The distribution of BDNF immunoreactivity was similar to that of TrkB in the molecular layer, Purkinje cells, and granule-cell layer. Using two-dimensional image analysis to measure immunoreactive signals within the molecular and granule-cell layers separately, we found that TrkB protein Sex: 36 male, 24 female t(58) = 0.060, P = 0.95 t(58) = 0.235, P = 0.81 t(58) = 0.397, P = 0.69 t(58) = 0.710, P = 0.48 Committed suicide in all four diagnostic groups: 20 yes, 40 no t(58) = 1.140, P = 0.26 t(58) = 0.801, P = 0.43 t(58) = 1.503, P = 0.14 t(55) = 1.807
Committed suicide in schizophrenia, bipolar disorder, and major depression: 20 yes, 25 no t(43) = 0.163, P = 0.87 t(43) = 0.549, P = 0.59 t(43) = 0.575, P = 0.57 t(40) = 0.779
Committed suicide in bipolar disorder: 9 yes, 6 no t(13) = 0.453, P = 0.66 t(13) = 0.065, P = 0.95 t(13) = 1.204, P = 0.25 t(13) = 0.626, P = 0.54
Psychosis in all four diagnostic groups: 26 yes, 34 no t(58) = 0.324, P = 0.75 t(58) = 0.974, P = 0.33 t(58) = 0.313, P = 0.76 t(58) = 1.296, P = 0.20
Psychosis in bipolar disorder: 11 yes, 4 no t(13) = 0.054, P = 0.96 t(13) = 0.359, P = 0.73 t(13) = 0.956, P = 0.36 t(13) = 0.339, P = 0.74 Severity of substance abuse: 42 none-little-social, 6 past moderate-severe, 11 current moderate-severe Welch's correction is applied. Fig. 2 . Distribution of the immunoreactivity normalized to the neuroanatomic area measured (IRn, arbitrary unit) for tyrosine kinase B (TrkB) in the molecular layer of the cerebellar inferior semilunar lobule across the four diagnostic groups (n = 15 each). There is a significant difference in TrkB IRn across the four diagnostic groups (F = 3.626, df = 3;56, P = 0.018, one-way analysis of variance), with the TrkB IRn significantly reduced in bipolar disorder compared to the control (P = 0.019, Tukey-Kramer post hoc test). The horizontal line in each group represents the mean value. The P values are two-tailed.
expression was significantly reduced (34% and 29%, respectively) in bipolar disorder compared to the control on the Tukey-Kramer post hoc test following ANOVA. However, the apparent reduction of TrkB protein expression in schizophrenia (12% and 12%, respectively) and major depression (26% and 12%, respectively) relative to the control was not statistically significant on the post hoc analyses. The apparent decrease in BDNF protein expression in each of 3 disease groups compared to the control did not reach statistical significance on ANOVA, which was probably due to large variability of data in relation to the small sample size in each diagnostic group. Using the Image-Pro Plus software in our study, the anatomically oriented AOI was precisely delineated to include several histologically intact areas not necessary to be contiguous and exclude staining artifacts, large vascular spaces, and areas of tissue folding. This approach provides a platform for objective measurement of immunoreactive signals in relatively large anatomic areas of interest. Still, the multi-step protocol of indirect immunohistochemistry on tissue sections is more or less subject to sample-to-sample variability, as are immunoblot analysis and enzyme-linked immunosorbent assay on tissue homogenates.
Concerning the potential confounding factors, the 4 diagnostic groups were matched for the age at death, postmortem interval, brain pH, and brain weight, and in almost all instances no significant linear correlations were found between these factors and the TrkB protein expression in each of the diagnostic groups. Therefore, ANCOVA was not performed with regard to these 4 continuous variables as covariates. In addition, the alteration in TrkB protein expression observed in our study did not appear to be related to the age at disease onset, duration of disease, or lifetime quantity of antipsychotic drugs. The storage time for frozen brain tissues showed no significant correlation with the TrkB protein expression, although the brains of patients with bipolar disorder and schizophrenia were kept frozen longer than the control. Moreover, we found no significant group differences in the TrkB protein expression with regard to committed suicide, psychosis, severity of substance abuse, and severity of alcohol abuse. In mice, shortterm exposure to ethanol was reported to be associated with decreased mRNA and protein expression of BDNF, but not TrkB, in the cerebellum (Wang et al., 2010) . A study by revealed no significant changes in mRNA levels of BDNF and TrkB in the prefrontal cortex of monkeys after a longterm exposure to haloperidol.
Taken together, our present study suggests that reduction of TrkB protein expression in the cerebellar inferior semilunar lobule of patients with bipolar disorder is attributable to the disease process, as there is no convincing evidence of influences from any of the potential confounding factors.
Immunoblot analysis using the same anti-TrkB antibody as that used for immunohistochemistry revealed in all 60 cases one TrkB-immunoreactive band of approximately 85 kDa, consistent with the C-terminus-truncated TrkB-T1 isoform (Luberg et al., 2010) , even though this anti-TrkB antibody was shown in other studies (Anger et al., 2007; Tan and Shepherd, 2006) to recognize both full-length and C-terminus-truncated isoforms of TrkB. It is possible that TrkB protein in the cerebellar inferior semilunar lobule consists predominantly of the TrkB-T1 isoform, and the levels of TrkB-FL and TrkB-T-Shc proteins are below the detection sensitivity of the method we used (since the β-actin-immunoreactive band of approximately 42 kDa was consistently observed in every case). A recent study of the expression profile of alternatively spiced transcripts of the human TrkB gene (Luberg et al., 2010) showed that TrkB-FL and TrkB-T1 mRNAs were most abundant in both cerebellum and prefrontal cortex, and the expression patterns of TrkB-FL and TrkB-T1 proteins differed from those of the transcripts encoding these proteins, suggesting that post-transcriptional mechanisms are involved. Immunoblotting data from adult monkey brains revealed that levels of C-terminus-truncated TrkB protein in the cerebellum and hippocampus were higher than those in other brain regions, while the expression of TrkB-FL protein was higher in the cerebral cortex (Ohira et al., 1999) .
For quantification of 85-kDa-TrkB signal intensity on immunoblots, in addition to controlling for lane-to-lane variability with β-actin in the same lane, we used the β-actinnormalized TrkB level of the 60-case pool in the same gel to control for gel-to-gel variability (Chong et al., 2008) . However, the apparent decreases in 85-kDa-TrkB levels in all 3 disease groups compared to the control did not reach statistical significance. This issue was probably related to a large degree of variability of the signal intensity relative to the small sample size in each diagnostic group.
While TrkB-FL is capable of mediating ligand-induced signal transduction via a tyrosine kinase-activated cascade, little is known about the function of truncated TrkB receptors. Neocortical pyramidal neurons and interneurons express both TrkB-FL and TrkB-T1, while astrocytes express only TrkB-T1 (Ohira and Hayashi, 2009 ). In the mammalian CNS, TrkB-FL expression is initiated in the early developmental period and maintained in the adult stage. In contrast, TrkB-T1 expression in the brain is very low in the early and middle developmental stages but is markedly up-regulated in the late developmental stage and maintained through the adult stage (Ohira et al., 1999) . This inflection of TrkB-T1 expression during CNS development coincides with the period of axonal remodeling and synaptogenesis (Ohira and Hayashi, 2009) . Specifically in the developing cerebellum, BDNF-induced TrkB-FL signaling is implicated in the formation of climbing fiber-Purkinje cell synapses, and the switch from full-length to truncated TrkB expression in inferior olivary neurons is associated with elimination of climbing-fiber multi-innervation to leave mature Purkinje cells mono-innervated (Sherrard et al., 2009 ). Furthermore, TrkB-T1 has been shown in TrkB cDNA transfected cell lines to be capable of mediating BDNF-induced signal transduction (Baxter et al., 1997) and may play a role in finetuning the growth of dendrites, axons, and synapses by interacting with TrkB-FL (Ohira and Hayashi, 2009; Yacoubian and Lo, 2000) . Different TrkB isoforms have differential effects on dendritic arborization, that is, while TrkB-FL stimulates proximal dendritic branching, TrkB-T1 promotes net elongation of distal dendrites (Yacoubian and Lo, 2000) . BDNFinduced TrkB-T1 signaling in astrocytes has been shown to mediate Ca 2+ release from intracellular stores and Ca 2+ entry from the extracellular space (Rose et al., 2003) and be involved in morphological alteration of astrocytes (Ohira and Hayashi, 2009 ), which may be crucial for the plasticity of tripartite synaptic transmission and the clearance of neurotransmitters (Halassa et al., 2007; Ohira and Hayashi, 2009; Rose et al., 2003) . Alternatively, it has been proposed that TrkB-T1 may function as a dominant negative receptor to sequester BDNF and inhibit its downstream effects, such as autophosphorylation of TrkB-FL, Ca 2+ efflux, neurite outgrowth, and cell survival activity (Ohira and Hayashi, 2009 ). Based on this proposed mechanism, the reduction of TrkB-T1 protein expression in the cerebellar cortex observed in our study may represent a compensatory response to deficiencies in synaptic plasticity mediated by other mechanisms in bipolar disorder (Fatemi et al., 2001; Gray et al., 2010) . In a recent study by Ernst et al. (2009) , 10 of 28 suicide completers showed marked downregulation of TrkB-T1 mRNA and protein in the frontal cortex. Reductions in mRNA levels of both BDNF and TrkB were reported in the prefrontal cortex of individuals with schizophrenia Weickert et al., 2003) . Specifically, decreased TrkB signaling might contribute to the reduced expression of glutamic acid decarboxylase (GAD) 67 (a γ-aminobutyric acid [GABA] synthesizing enzyme) in the parvalbumin-expressing subpopulation of inhibitory GABAergic interneurons, resulting in dysfunction of the perisomatic inhibitory regulation of pyramidal neurons during working memory processes in schizophrenia (Akbarian and Huang, 2006; Lewis et al., 2005) . In cerebellum-specific TrkB-lacking mice, the mature cerebellum contained normal numbers and positions of all cell types but showed decreased expression of GAD65 and the GABA transporter 1 within the termini of inhibitory GABAergic interneurons and Purkinje cells (Rico et al., 2002) . Postmortem studies in schizophrenia have consistently revealed decreases in TrkB and GAD67 mRNA expression in the prefrontal cortex and hippocampus (Akbarian and Huang, 2006; Guidotti et al., 2000; Hashimoto et al., 2005; Lewis et al., 2005; Thompson Ray et al., 2011) . In the cerebellar cortex from the Stanley Foundation Neuropathology Consortium, decreased GAD67 protein levels were found in individuals with schizophrenia and bipolar disorder (Fatemi et al., 2005; Guidotti et al., 2000) , the observation that complements our finding of reduced TrkB protein expression in bipolar disorder from the same cohort.
The role of the cerebellum in modulating and coordinating cognitive activity is suggested by its neural connection with the prefrontal cortex (Ramnani, 2006) . In the present study, we reported decreased TrkB protein expression in the cerebellar inferior semilunar lobule of patients with bipolar disorder. The truncated isoform TrkB-T1 appeared to represent the majority of TrkB protein expressed in this specific cerebellar region. Our study suggests that the alteration in TrkB protein expression in bipolar disorder is attributable to the disease process, as we found no significant difference in TrkB protein expression between the psychotic and non-psychotic groups. Given the role of TrkB signaling in synaptic plasticity, decreased TrkB expression in the cerebellum of patients with bipolar disorder suggests that dysregulation of neurotrophin-induced TrkB activation in the cerebellum may play a role in the pathophysiology of bipolar disorder. In light of our findings, further investigation as to how TrkB down-regulation affects the inhibitory GABAergic interneurons in the cerebellar cortex of patients with bipolar disorder is warranted.
